Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Epidermal growth factor receptor Stories

2010-12-02 07:00:00

BURLINGTON, Mass., Dec. 2, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the testing rate for epidermal growth factor receptor (EGFR) mutation--a predictor of response to Genentech/Roche/OSI/Chugai's EGFR inhibitor Tarceva--in non-small-cell lung cancer (NSCLC) patients will increase by approximately 50 percent over the next 12 months, according to surveyed U.S. oncologists. In line with...

2010-11-17 13:41:47

Scientists believe they may have found a new target for treating triple negative breast cancer "“ one of the more difficult breast cancers to treat successfully and for which there is no targeted therapy at present. Triple negative breast cancer (TNBC) is a cancer that does not express receptors for oestrogen (ER), progesterone (PR) or the human epidermal growth factor (HER2). It tends to be more aggressive, occurs more often in younger women, and is difficult to treat successfully as...

2010-11-11 07:59:07

(Ivanhoe Newswire) -- Lung cancer, the most common cause of cancer-related death in men and women, is responsible for 1.3 million deaths worldwide annually.  The most common cause of lung cancer is long-term exposure to tobacco smoke, however, the occurrence of lung cancer in never-smokers accounts for as many as 15 percent of cases.  In a pilot study, different DNA alterations in the tumor genomes were found in those who smoke and never smoked, which may represent two different...

2010-11-10 06:00:00

BEIJING, Nov. 10, 2010 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based advanced in-vitro diagnostic ("IVD") company, today announced that it has received approval for its real-time PCR-based Epidermal Growth Factor Receptor ("EGFR") Assay (the "EGFR PCR Assay") for the use of lung cancer targeted drugs from the State Food and Drug Administration of China (the "SFDA"). The EGFR PCR Assay is used for the detection of the...

2010-11-08 08:16:00

OMAHA, Neb., Nov. 8, 2010 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO) today announced completion of a development study of several new assays to detect genetic mutations using the Company's proprietary Co-amplification at Lower Denaturing Temperature PCR (COLD-PCR) technology in the Epidermal Growth Factor Receptor (EGFR) gene. EGFR mutations are found in a number of cancers, including lung and colorectal cancers. Several new targeted cancer therapeutics...

2010-10-27 10:38:00

PRINCETON, N.J., Oct. 27 /PRNewswire/ -- Laureate Pharma, Inc., a full-service contract development and manufacturing organization, announced today that they have entered into a development and manufacturing agreement to produce AV-203, AVEO Pharmaceutical's (Cambridge, MA) novel monoclonal antibody targeted against ErbB3. Laureate's services will include process development, protein production, purification and aseptic filling of AP-203 for AVEO. The project is presently underway and...

2010-10-27 02:21:47

Even though the cancer-treatment agent cetuximab is not considered effective treatment for KRAS (a gene)-mutated metastatic colorectal tumors, new research indicates that patients with colorectal cancer not responding to chemotherapy and a certain variation of this gene who were treated with cetuximab had longer overall and progression-free survival than patients with other KRAS-mutations, according to a study in the October 27 issue of JAMA. "Recent retrospective correlative analyses of...

2010-10-12 17:58:41

Lung cancer patients who have already been treated with the EGFR inhibitors erlotinib or gefitinib seem to gain further benefits in terms of progression-free survival and tumor shrinkage when treated with the new drug afatinib, the results of a Phase IIb/III trial show. At the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy, Dr Vincent Miller from Memorial Sloan-Kettering Cancer Center in New York, USA, reported findings from the LUX-Lung 1 trial of afatinib...

2010-10-01 14:20:35

Large, global phase IV study extends therapy benefits beyond standard patient population Featured in the October edition of the Journal of Thoracic Oncology (JTO), data from The Tarceva Lung Cancer Survival Treatment (TRUST) confirms the safety and efficacy profile of erlotinib, a highly potent oral active, reversible inhibitor of epidermal growth factor receptor (EGFR) tyrosine-kinase (TK) activity in a large heterogeneous non-small cell lung cancer (NSCLC) population. Erlotinib has been...

2010-09-29 12:31:33

African-American patients with non-small cell lung cancer are just as likely to display an epidermal growth factor receptor (EGFR) mutation in tumors as Caucasians, which suggests they are as likely to benefit from targeted therapies such as erlotinib. "This study has immediate implications for patient management. Patients with EGFR mutations have a much better prognosis and respond better to erlotinib than those who do not," said Ramsi Haddad, Ph.D., director of the Laboratory of...